ArticleHeliyon2018
KUS121, an ATP regulator, mitigates chorioretinal pathologies in animal models of age-related macular degeneration.
Article in Heliyon, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 13 citations in OpenAlex.
- Post hoc analysis of a randomized placebo-controlled trial suggests potential visual benefits of branched-chain amino acids in retinitis pigmentosa.Scientific reports · 2025Trial
- Trial
- Valosin-containing protein modulator KUS121 protects retinal neurons in a rat model of anterior ischemic optic neuropathy.Scientific reports · 2025Article
- Macular white dot lesions with hyperreflective optical coherence tomography findings in cynomolgus and rhesus monkeys.Molecular vision · 2024Article
- Involvement of endothelins in neuroprotection of valosin-containing protein modulators against retinal ganglion cell damage.Scientific reports · 2022Article
- Branched Chain Amino Acids Promote ATP Production Via Translocation of Glucose Transporters.Investigative ophthalmology & visual science · 2022Article
- NAMPT-dependent NADCell death discovery · 2022Article
- KUS121 attenuates the progression of monosodium iodoacetate-induced osteoarthritis in rats.Scientific reports · 2021Article
- A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis.Scientific reports · 2020Article
- Oxidative stress in the light-exposed retina and its implication in age-related macular degeneration.Redox biology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related macular degeneration (AMD) is a leading cause of blindness among elderly people. The appearance of drusen is a clinical manifestation and a harbinger of both exudative and atrophic AMD. Recently, antibody-based medicines have been used to treat the exudative type. However, they do not restore good vision in patients. Moreover, no effective treatment is available for atrophic AMD. We have created small chemicals (Kyoto University Substances; KUSs) that act as ATP regulators inside cells. In the present study, we examined the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.